Annual FCF
-$22.94 M
+$5.65 M+19.78%
December 31, 2023
Summary
- As of February 7, 2025, CDTX annual free cash flow is -$22.94 million, with the most recent change of +$5.65 million (+19.78%) on December 31, 2023.
- During the last 3 years, CDTX annual FCF has risen by +$31.66 million (+57.99%).
- CDTX annual FCF is now -2088.65% below its all-time high of -$1.05 million, reached on December 31, 2013.
Performance
CDTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$36.80 M
+$66.98 M+64.54%
September 30, 2024
Summary
- As of February 7, 2025, CDTX quarterly free cash flow is -$36.80 million, with the most recent change of +$66.98 million (+64.54%) on September 30, 2024.
- Over the past year, CDTX quarterly FCF has dropped by -$23.90 million (-185.28%).
- CDTX quarterly FCF is now -231.60% below its all-time high of $27.96 million, reached on September 30, 2022.
Performance
CDTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$160.15 M
-$35.04 M-28.01%
September 30, 2024
Summary
- As of February 7, 2025, CDTX TTM free cash flow is -$160.15 million, with the most recent change of -$35.04 million (-28.01%) on September 30, 2024.
- Over the past year, CDTX TTM FCF has dropped by -$137.21 million (-598.21%).
- CDTX TTM FCF is now -38865.45% below its all-time high of -$411.00 thousand, reached on March 31, 2014.
Performance
CDTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
CDTX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +19.8% | -185.3% | -598.2% |
| 3 y3 years | +58.0% | -234.8% | -907.8% |
| 5 y5 years | +59.7% | -234.8% | -907.8% |
CDTX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +19.8% | -231.6% | +64.5% | <-9999.0% | at low |
| 5 y | 5-year | at high | +58.0% | -231.6% | +64.5% | <-9999.0% | at low |
| alltime | all time | -2088.7% | +59.7% | -231.6% | +64.5% | <-9999.0% | at low |
Cidara Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$36.80 M(-64.5%) | -$160.15 M(+28.0%) |
| Jun 2024 | - | -$103.78 M(+1456.6%) | -$125.11 M(+572.2%) |
| Mar 2024 | - | -$6.67 M(-48.3%) | -$18.61 M(-18.9%) |
| Dec 2023 | -$22.94 M(-19.8%) | -$12.90 M(+633.0%) | -$22.94 M(-26.1%) |
| Sep 2023 | - | -$1.76 M(-164.8%) | -$31.05 M(+2245.0%) |
| Jun 2023 | - | $2.71 M(-124.7%) | -$1.32 M(-91.7%) |
| Mar 2023 | - | -$10.99 M(-47.7%) | -$15.89 M(-44.4%) |
| Dec 2022 | -$28.59 M(+13.1%) | -$21.01 M(-175.1%) | -$28.59 M(+27.1%) |
| Sep 2022 | - | $27.96 M(-335.9%) | -$22.49 M(-64.0%) |
| Jun 2022 | - | -$11.85 M(-50.0%) | -$62.44 M(+32.4%) |
| Mar 2022 | - | -$23.69 M(+58.9%) | -$47.16 M(+86.6%) |
| Dec 2021 | -$25.27 M(-53.7%) | -$14.91 M(+24.4%) | -$25.27 M(+17.6%) |
| Sep 2021 | - | -$11.98 M(-450.1%) | -$21.49 M(-9.1%) |
| Jun 2021 | - | $3.42 M(-289.6%) | -$23.65 M(-42.7%) |
| Mar 2021 | - | -$1.80 M(-83.8%) | -$41.24 M(-24.5%) |
| Dec 2020 | -$54.60 M(+91.1%) | -$11.13 M(-21.3%) | -$54.60 M(-6.9%) |
| Sep 2020 | - | -$14.14 M(-0.2%) | -$58.67 M(+110.2%) |
| Jun 2020 | - | -$14.17 M(-6.6%) | -$27.91 M(+5.0%) |
| Mar 2020 | - | -$15.16 M(-0.2%) | -$26.58 M(-7.0%) |
| Dec 2019 | -$28.57 M | -$15.20 M(-191.4%) | -$28.57 M(+5.5%) |
| Sep 2019 | - | $16.62 M(-229.5%) | -$27.08 M(-52.1%) |
| Jun 2019 | - | -$12.83 M(-25.2%) | -$56.56 M(-4.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$17.16 M(+25.2%) | -$59.28 M(+4.2%) |
| Dec 2018 | -$56.88 M(+13.3%) | -$13.71 M(+6.5%) | -$56.88 M(+7.7%) |
| Sep 2018 | - | -$12.87 M(-17.3%) | -$52.81 M(-1.8%) |
| Jun 2018 | - | -$15.56 M(+5.4%) | -$53.80 M(+6.9%) |
| Mar 2018 | - | -$14.75 M(+53.2%) | -$50.33 M(+0.2%) |
| Dec 2017 | -$50.22 M(+25.0%) | -$9.63 M(-30.5%) | -$50.22 M(-4.2%) |
| Sep 2017 | - | -$13.86 M(+14.6%) | -$52.42 M(+13.2%) |
| Jun 2017 | - | -$12.09 M(-17.4%) | -$46.32 M(+5.6%) |
| Mar 2017 | - | -$14.63 M(+23.6%) | -$43.87 M(+9.2%) |
| Dec 2016 | -$40.17 M(+48.1%) | -$11.84 M(+52.6%) | -$40.17 M(+13.1%) |
| Sep 2016 | - | -$7.76 M(-19.5%) | -$35.53 M(-0.3%) |
| Jun 2016 | - | -$9.63 M(-11.9%) | -$35.63 M(+11.4%) |
| Mar 2016 | - | -$10.94 M(+51.9%) | -$31.99 M(+17.9%) |
| Dec 2015 | -$27.13 M(+211.8%) | -$7.20 M(-8.3%) | -$27.13 M(+16.7%) |
| Sep 2015 | - | -$7.85 M(+31.1%) | -$23.25 M(+23.8%) |
| Jun 2015 | - | -$5.99 M(-1.5%) | -$18.78 M(+30.7%) |
| Mar 2015 | - | -$6.08 M(+83.3%) | -$14.37 M(+65.2%) |
| Dec 2014 | -$8.70 M(+730.2%) | -$3.32 M(-2.2%) | -$8.70 M(+61.6%) |
| Sep 2014 | - | -$3.39 M(+114.5%) | -$5.38 M(+170.2%) |
| Jun 2014 | - | -$1.58 M(+284.7%) | -$1.99 M(+384.7%) |
| Mar 2014 | - | -$411.00 K | -$411.00 K |
| Dec 2013 | -$1.05 M | - | - |
FAQ
- What is Cidara Therapeutics annual free cash flow?
- What is the all time high annual FCF for Cidara Therapeutics?
- What is Cidara Therapeutics annual FCF year-on-year change?
- What is Cidara Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Cidara Therapeutics?
- What is Cidara Therapeutics quarterly FCF year-on-year change?
- What is Cidara Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Cidara Therapeutics?
- What is Cidara Therapeutics TTM FCF year-on-year change?
What is Cidara Therapeutics annual free cash flow?
The current annual FCF of CDTX is -$22.94 M
What is the all time high annual FCF for Cidara Therapeutics?
Cidara Therapeutics all-time high annual free cash flow is -$1.05 M
What is Cidara Therapeutics annual FCF year-on-year change?
Over the past year, CDTX annual free cash flow has changed by +$5.65 M (+19.78%)
What is Cidara Therapeutics quarterly free cash flow?
The current quarterly FCF of CDTX is -$36.80 M
What is the all time high quarterly FCF for Cidara Therapeutics?
Cidara Therapeutics all-time high quarterly free cash flow is $27.96 M
What is Cidara Therapeutics quarterly FCF year-on-year change?
Over the past year, CDTX quarterly free cash flow has changed by -$23.90 M (-185.28%)
What is Cidara Therapeutics TTM free cash flow?
The current TTM FCF of CDTX is -$160.15 M
What is the all time high TTM FCF for Cidara Therapeutics?
Cidara Therapeutics all-time high TTM free cash flow is -$411.00 K
What is Cidara Therapeutics TTM FCF year-on-year change?
Over the past year, CDTX TTM free cash flow has changed by -$137.21 M (-598.21%)